Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 112

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 112
---
 our products and services, including defects in our engineering and design processes, as well as defects in third -partycomponents included in our products. In addition, new products or enhancements may contain undetected errors or performance problems that, despite testing, are discovered only after commercial shipment. Defects or errors in our test results may discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may affect our reputation substantially and could adversely affect our operating margins. Identifying the root cause of quality issues, particularly those sourced from third parties, may be difficult, which increases the time needed to address quality issues as they arise, and increases the risk that similar 33 problems could recur. As our products are designed to be used to perform complex genomic analysis, we expect that our customers will have an increased sensitivity to such defects. If we do not meet applicable regulatory or quality standards, our services may be subject to refunds, and, under certain circumstances, we may be required to notify applicable regulatory authorities about such refunds. If our products are subject to refunds or delivery holds, our reputation, business, financial condition, or results of operations could be adversely affected. We rely on a limited number of suppliers or, in some cases, sole suppliers for raw materials, key components or laboratory instruments, and an interruption in our ability to obtain such materials and services could adversely affect our business. We do not have manufacturing capabilities and do not plan to develop such capacity in the foreseeable future. Accordingly, we rely on a limited number of suppliers, or, in some cases, sole suppliers, including Illumina, Amoy Diagnostics Co., Ltd., Sophia Genetics SA and GNX Data Systems Ltd., for certain laboratory substances used in the chemical reactions incorporated into our processes, which we refer to as reagents, as well as sequencers and other equipment and materials which we use in our laboratory operations. In addition, we do not have short- or long -termagreements with most of these suppliers, and these suppliers could cease supplying these materials and equipment at any time or fail to provide us with sufficient quantities of materials or materials that meet our specifications. Our laboratory operations could be interrupted if we encounter delays or difficulties in securing these reagents, sequencers or other equipment or materials, and if we cannot obtain an acceptable substitute. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. We rely on Illumina as the sole supplier of next generation sequencers and associated reagents and as the sole provider of maintenance and repair services for